Vivos Therapeutics reported Q3 2026 financial results, highlighting a 24% sequential revenue increase to $6.4 million and an 18% year-over-year improvement in operating loss. The company successfully regained compliance with Nasdaq's stockholders' equity requirement following debt-for-equity exchanges and the closing of its SOD Sciences transaction.
Term
Q3 2026
“During the third quarter of 2026, we took decisive steps to reduce costs and strengthen our balance sheet. Our operating loss improved 18% compared to the prior-year quarter, general and administrative and sales and marketing expenses together declined by $1.6 million, and we have now eliminated an estimated $5 million or more in annual operating costs, with further efficiencies underway.”
Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer
“We are also pursuing a number of clinical initiatives at our SCN and SAMC centers, including EEG testing and treatment for insomnia and other non-OSA sleep disorders, the distribution and set-up of PAP and CPAP treatments, and remote patient monitoring of CPAP users, together with the renegotiation of our payer contracts. We expect these initiatives to contribute to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.”
Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer
Vivos Therapeutics is transitioning from a legacy dentist-focused model to a medical-provider focused sales and distribution model, highlighted by the acquisition of The Sleep Center of Nevada and a transaction with SOD Sciences. The company faces significant challenges regarding its Nasdaq listing requirements and the integration of its new business model while managing substantial indebtedness.
Vivos Therapeutics received a letter from Nasdaq confirming that the company has regained compliance with the minimum stockholders' equity requirement of $2.5 million under Listing Rule 5550(b)(1). The compliance was achieved following a transaction involving the issuance of Series C Convertible Preferred Stock, which is expected to increase stockholders' equity by more than $10 million. The company must continue to evidence compliance in its next periodic report to avoid potential delisting.
Vivos Therapeutics Signs $12M M&A Deal with SOD Sciences, Inc.
Vivos Therapeutics completed the acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia early-warning test. The transaction was valued at $12 million, paid via the issuance of 12,000 shares of Series C Convertible Preferred Stock, and is expected to add over $10 million to Vivos' stockholders' equity.
Value
$12M
Counterparty
SOD Sciences, Inc.
“Today Vivos became more than a healthcare company just treating sleep apnea. We expect this transaction to add more than $10 million to our stockholders’ equity, and we now own half of a test designed to identify patients whose sleep apnea may be contributing to chronic disease.”
R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos
Vivos Therapeutics Signs $12M M&A Deal with SOD Sciences, Inc.
Vivos Therapeutics entered into a definitive agreement to acquire an 11% equity stake in SOD Sciences and a 50% co-ownership interest in a proprietary pseudohypoxia early-warning test. The transaction is valued at $12 million, paid via the issuance of 12,000 shares of newly created Series C Convertible Preferred Stock, and is intended to bolster stockholders' equity for Nasdaq compliance.
Vivos Therapeutics dismissed Baker Tilly US, LLP as its independent registered public accounting firm and appointed Haynie & Company as its new auditor for the fiscal year ending December 31, 2026. The change was approved by the Audit Committee on September 29, 2026, and the company reported no disagreements with the outgoing firm regarding accounting principles or practices.